Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume -, Issue -, Pages 115915
Publisher
Elsevier BV
Online
2023-11-04
DOI
10.1016/j.ejmech.2023.115915
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy
- (2023) Wei-Xin Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Umbralisib: First Approval
- (2021) Sohita Dhillon et al. DRUGS
- Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses
- (2021) Daniel J. Landsburg et al. BRITISH JOURNAL OF HAEMATOLOGY
- Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review
- (2021) Yuanze Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Pharmacological Evaluation of First‐in‐Class Multitarget N ‐Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors
- (2020) Daniel A. Rodrigues et al. ChemMedChem
- CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action
- (2020) Cheng Hu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors
- (2020) Ashish Thakur et al. JOURNAL OF MEDICINAL CHEMISTRY
- Multitarget inhibition of histone deacetylase (HDAC) and phosphatidylinositol‐3‐kinase (PI3K): Current and future prospects
- (2020) Carlos Alberto Manssour Fraga et al. ChemMedChem
- Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
- (2019) Xinyu Li et al. HAEMATOLOGICA
- Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases
- (2019) Kehui Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Alpelisib: First Global Approval
- (2019) Anthony Markham DRUGS
- Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts
- (2018) Xiaodong Ma et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma
- (2018) Dizhong Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
- (2018) Ewgenij Proschak et al. JOURNAL OF MEDICINAL CHEMISTRY
- Duvelisib: First Global Approval
- (2018) Hannah A. Blair DRUGS
- Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy
- (2018) Yepeng Luan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes
- (2017) Ercument Dirice et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
- (2017) Liyan Chen et al. Oncotarget
- Design, synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-c]quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors
- (2017) Yichao Wu et al. RSC Advances
- Multitarget Drug Discovery and Polypharmacology
- (2016) Maria Laura Bolognesi et al. ChemMedChem
- Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities
- (2016) Yong Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC
- (2016) Junjie Piao et al. Oncotarget
- PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1-Dependent Mechanisms In Vitro and In Vivo
- (2014) M. Rahmani et al. CLINICAL CANCER RESEARCH
- Idelalisib: First Global Approval
- (2014) Anthony Markham DRUGS
- Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
- (2014) Roelof W F van Leeuwen et al. LANCET ONCOLOGY
- Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
- (2012) C. Qian et al. CLINICAL CANCER RESEARCH
- Polypharmacology: drug discovery for the future
- (2012) A Srinivas Reddy et al. Expert Review of Clinical Pharmacology
- Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors
- (2011) Christoph M. Dehnhardt et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor
- (2010) Aranapakam M. Venkatesan et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
- (2010) Alberto M. Martelli et al. Cancers
- Network pharmacology: the next paradigm in drug discovery
- (2008) Andrew L Hopkins Nature Chemical Biology
- Class I PI3K in oncogenic cellular transformation
- (2008) L Zhao et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now